within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01EX24_Surufatinib;

model Surufatinib
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.81,
    Cl = 2.7722222222222223e-06,
    adminDuration = 600,
    adminMass = 300 / 1000000,
    adminCount = 1,
    Vd = 0.0544,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.011383333333333334,
    Tlag = 10.200000000000001,
    Vdp = 0.107,
    k12 = 5.888888888888889e-06,
    k21 = 5.888888888888889e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Surufatinib</td></tr><tr><td>ATC code:</td><td>L01EX24</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>300</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>54.4</td><td>L</td></tr>
    <tr><td>clearance:</td><td>9.98</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Surufatinib is an oral small molecule tyrosine kinase inhibitor targeting VEGFR, FGFR1, and CSF-1R. It is developed for the treatment of neuroendocrine tumors (NETs) and has received approval in China for the treatment of non-pancreatic neuroendocrine tumors.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics reported for adult patients with advanced solid tumors, typically Asian (Chinese) individuals. Data most extensively reported for the oral administration of surufatinib at steady state.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.L.L01EX24 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Surufatinib;
